• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Olema Pharmaceuticals Inc.

    12/19/25 2:35:45 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OLMA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001336504
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Olema Pharmaceuticals, Inc.
    SEC File Number
    001-39712
    Address of Issuer
    780 BRANNAN STREET
    SAN FRANCISCO
    CALIFORNIA
    94103
    Phone
    (415) 651-3316
    Name of Person for Whose Account the Securities are To Be Sold
    CLARK IAN T
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    2648007873501.646865992312/19/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common12/19/2025Option Granted - 08/12/2020IssuerCheckbox not checked20969012/19/2025Cash
    Common12/19/2025Option Granted - 06/17/2022IssuerCheckbox not checked2152012/19/2025Cash
    Common12/19/2025Option Granted - 06/16/2023IssuerCheckbox not checked2152012/19/2025Cash
    Common12/19/2025Option Granted - 06/11/2025IssuerCheckbox not checked1207012/19/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    12/19/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Ian T. Clark

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $OLMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OLMA

    DatePrice TargetRatingAnalyst
    1/7/2026$40.00Overweight
    Piper Sandler
    10/8/2025$20.00Buy
    Guggenheim
    8/12/2025$20.00 → $21.00Buy
    Citigroup
    4/2/2024$24.00Buy
    Goldman
    1/30/2024$20.00Buy
    Citigroup
    7/21/2023$21.00Outperform
    Oppenheimer
    5/5/2023$16.00Overweight
    CapitalOne
    2/22/2023$12.00Outperform
    Credit Suisse
    More analyst ratings

    $OLMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Bohen Sean gifted 8,500 shares, decreasing direct ownership by 3% to 237,650 units (SEC Form 4)

    4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    12/30/25 4:05:14 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Harmon Cyrus sold $82,195 worth of shares (2,881 units at $28.53), decreasing direct ownership by 0.39% to 741,259 units (SEC Form 4)

    4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    12/29/25 9:55:05 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Clark Ian T sold $7,873,109 worth of shares (264,800 units at $29.73) and exercised 264,800 shares at a strike of $4.61 (SEC Form 4)

    4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    12/23/25 9:42:34 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OLMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to 8 new employees to purchase an aggregate of 223,500 shares of the Company's common stock, effective as of January 2, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance w

    1/5/26 4:30:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference

    SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 13, 2025 at 11:15 a.m. PT (2:15 p.m. ET). A live webcast of the presentation and any accompanying materials will be available in the Events and Presentations section of Olema's Investor Relations website at ir.olema

    1/5/26 7:00:00 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 65,000 shares of the Company's common stock, effective as of December 1, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance

    12/2/25 4:30:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OLMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bain Capital Life Sciences Investors, Llc bought $1,727,370 worth of shares (300,000 units at $5.76) and disposed of 3,500,000 shares (SEC Form 4)

    4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    1/13/25 4:34:40 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) and bought $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)

    4/A - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    12/18/24 6:52:04 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)

    4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

    12/17/24 7:52:19 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OLMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Olema Pharmaceuticals with a new price target

    Piper Sandler initiated coverage of Olema Pharmaceuticals with a rating of Overweight and set a new price target of $40.00

    1/7/26 9:13:12 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Olema Pharmaceuticals with a new price target

    Guggenheim initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $20.00

    10/8/25 8:35:33 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup reiterated coverage on Olema Pharmaceuticals with a new price target

    Citigroup reiterated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $21.00 from $20.00 previously

    8/12/25 8:24:27 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OLMA
    SEC Filings

    View All

    SEC Form 144 filed by Olema Pharmaceuticals Inc.

    144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/22/25 2:14:43 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Olema Pharmaceuticals Inc.

    144 - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/19/25 2:35:45 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Olema Pharmaceuticals Inc.

    S-3ASR - Olema Pharmaceuticals, Inc. (0001750284) (Filer)

    12/11/25 4:48:15 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OLMA
    Financials

    Live finance-specific insights

    View All

    Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

    Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with ER+/HER2- advanced or metastatic breast cancer With a median follow-up of 12 months, median progression-free survival (PFS) has not been reached6-month PFS rate was 73% in all patients, 81% in patients with ESR1 mutations, 70% in ESR1 wild-type patients, and 68% in patients with prior CDK4/6 inhibitor treatment; data continue to mature Conference call today at 8:00 a.m. ET SAN FRANCISCO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA),

    12/10/24 7:00:00 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

    SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that it will present new data from the Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib at the San Antonio Breast Cancer Symposium (SABCS 2024) being held December 10-13, 2024, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Poster Details Title: A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patien

    11/25/24 5:30:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

    Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either therapy85% clinical benefit rate (CBR) observed to date across all CBR-eligible patients supports promising preliminary efficacy profile of the palazestrant-ribociclib combination Olema will host an investor conference call today at 8:00 a.m. ET SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted the

    5/15/24 7:01:00 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OLMA
    Leadership Updates

    Live Leadership Updates

    View All

    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 19,800 shares of the Company's common stock, effective as of March 3, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance w

    3/4/25 4:30:00 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

    SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Shawnte M. Mitchell, J.D., as Chief Legal Officer and Corporate Secretary. "We are pleased to welcome Shawnte to our executive team to lead our Legal function as we progress both our late-stage palazestrant programs and our OP-3136 KAT6 program through clinical development," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "Her extensive e

    2/18/25 7:00:00 AM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

    ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

    11/24/24 7:27:00 PM ET
    $LIAN
    $MGTX
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $OLMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

    SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/11/24 4:30:15 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Olema Pharmaceuticals Inc.

    SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/4/24 7:49:50 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Olema Pharmaceuticals Inc.

    SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    11/14/24 4:34:56 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care